Morgan Stanley’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-252,093
| Closed | -$12.1M | – | 8461 |
|
|
2025
Q3 | $12.1M | Sell |
252,093
-110,643
| -31% | -$3.07M | ﹤0.01% | 3377 |
|
|
2025
Q2 | $5.8M | Buy |
362,736
+76,991
| +27% | +$1.25M | ﹤0.01% | 3938 |
|
|
2025
Q1 | $4.35M | Buy |
285,745
+81,463
| +40% | +$1.31M | ﹤0.01% | 4043 |
|
|
2024
Q4 | $4.14M | Sell |
204,282
-33,467
| -14% | -$843K | ﹤0.01% | 4157 |
|
|
2024
Q3 | $6.11M | Sell |
237,749
-90,193
| -28% | -$1.51M | ﹤0.01% | 3816 |
|
|
2024
Q2 | $4.22M | Buy |
327,942
+311,623
| +1,910% | +$5.01M | ﹤0.01% | 4026 |
|
|
2024
Q1 | $374K | Buy |
16,319
+3,971
| +32% | +$140K | ﹤0.01% | 5443 |
|
|
2023
Q4 | $323K | Buy |
12,348
+8,728
| +241% | +$175K | ﹤0.01% | 5770 |
|
|
2023
Q3 | $102K | Sell |
3,620
-1,220
| -25% | -$35.7K | ﹤0.01% | 5885 |
|
|
2023
Q2 | $147K | Sell |
4,840
-22,624
| -82% | -$578K | ﹤0.01% | 5773 |
|
|
2023
Q1 | $516K | Buy |
27,464
+26,130
| +1,959% | +$431K | ﹤0.01% | 5237 |
|
|
2022
Q4 | $13.6K | Sell |
1,334
-585
| -30% | -$9.4K | ﹤0.01% | 6829 |
|
|
2022
Q3 | $51K | Sell |
1,919
-351
| -15% | -$12.8K | ﹤0.01% | 6397 |
|
|
2022
Q2 | $103K | Sell |
2,270
-1,152
| -34% | -$90.9K | ﹤0.01% | 6264 |
|
|
2022
Q1 | $337K | Buy |
3,422
+75
| +2% | +$7.02K | ﹤0.01% | 5618 |
|
|
2021
Q4 | $511K | Buy |
3,347
+962
| +40% | +$142K | ﹤0.01% | 5528 |
|
|
2021
Q3 | $323K | Buy |
2,385
+560
| +31% | +$76.7K | ﹤0.01% | 5742 |
|
|
2021
Q2 | $269K | Buy |
+1,825
| New | +$280K | ﹤0.01% | 5867 |
|
Morgan Stanley's TRML Position: Q4 2025 in Review
Morgan Stanley sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 252,093 shares — an estimated $12.1M sold.
Morgan Stanley first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $12.1M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Morgan Stanley reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 252,093 Tourmaline Bio shares in Q4 2025, an estimated $12.1M.
- Morgan Stanley first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Morgan Stanley's Tourmaline Bio position peaked at $12.1M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.